EP Patent

EP2986736A2 — Gene fusions and gene variants associated with cancer

Assigned to Life Technologies Corp · Expires 2016-02-24 · 10y expired

What this patent protects

The disclosure provides gene fusions, gene variants, and novel associations with disease states, as well as kits, probes, and methods of using the same.

USPTO Abstract

The disclosure provides gene fusions, gene variants, and novel associations with disease states, as well as kits, probes, and methods of using the same.

Drugs covered by this patent

Patent Metadata

Patent number
EP2986736A2
Jurisdiction
EP
Classification
—
Expires
2016-02-24
Drug substance claim
No
Drug product claim
No
Assignee
Life Technologies Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.